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ABSTRACT
Background: Pregnancy at early age is the most significant modifiable factor 
which consistently decreases lifetime breast cancer risk. However, the underlying 
mechanisms haven’t been conclusively identified. Studies in mice suggest a reduction 
in progesterone-receptor (PR) sensitive epithelial cells as well as a downregulation 
of the Wnt signaling pathway as being one of the main mechanisms for the protective 
effect of early pregnancy. The aim of our study was to validate these findings in 
humans.
Methods: We collected benign breast tissue of 125 women who had been stratified 
according to age at first pregnancy and the occurrence of subsequent breast cancer, 
and performed immunohistochemistry for PR, Wnt4 and the Wnt-target Versican.
Results: The number of PR positive epithelial cells was significantly lower in the 
group of women with early pregnancy and no subsequent breast cancer compared to 
the group of nulliparous women with subsequent invasive breast cancer (p = 0.0135). 
In women with early pregnancy, expression of Versican and Wnt4 was significantly 
lower compared to nulliparous women (p = 0.0036 and p = 0.0241 respectively), 
and Versican expression was also significant lower compared to women with late 
pregnancy (p < 0.0001).
Discussion: Our results confirm prior observations in mice and suggest a 
role of downregulation of epithelial Wnt signaling in the protective effect of early 
pregnancy in humans. This results in a decreased proliferation of stem/progenitor 
cells; therefore, the Wnt signaling pathway may represent a potential target for breast 
cancer prevention in humans.
INTRODUCTION
With an estimated 1.7 million cases per year 
worldwide, breast cancer is the most frequent cancer in 
women. Despite substantial progress in early detection 
and treatment, 521.900 women die of their disease each 
year [1]. Several risk factors for breast cancer have been 
described. One of the strongest modifiable factors which 
consistently decreases lifetime breast cancer risk, is 
pregnancy [2-4]. 
The protective effect of a full-term pregnancy is 
most pronounced for a pregnancy occurring before the age 
of 20, resulting in a lifetime breast cancer risk reduction 
of >50% in comparison to nulliparous women [2]. While 
the protective effect becomes negligible for women with 
first full-term pregnancies between the age of 30 and 
34, an increased risk can be observed in women with a 
first pregnancy over the age of 35 [5]. Interestingly, a 
transient increase in breast cancer risk can be observed 
in women over the age of 25 years immediately after 
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delivery, delaying the protective effect by up to 10 years 
[3]. In addition to early age at first pregnancy, multiple 
pregnancies as well as prolonged breast feeding also 
decrease the life-time risk for breast cancer to a smaller 
degree [6]. It seems that parity specifically protects against 
hormone receptor positive breast cancers, whereas the risk 
for hormone receptor negative cancers is not influenced 
by age at first pregnancy or parity [7]. The effect of 
pregnancy-induced protection against breast cancer has 
also been observed in rodent models [8, 9].
The underlying mechanisms of this protective 
effect have not been conclusively identified and may 
not be explainable by a solitary mechanism, but by a 
combination of mechanisms [6] such as alterations in 
circulating hormones [6, 8], a parity induced decrease 
of hormone responsiveness of the mammary gland [6, 
8], long-lasting alterations in the composition of the 
mammary extracellular matrix (ECM) [6, 8, 10], as well as 
a terminal epithelial cell differentiation occurring during 
pregnancy [6, 11-13]. 
Parity induced alteration of cell fate of specific 
mammary epithelial cells including mammary stem/
progenitor cells represents another promising explanation. 
Persistent changes in transduction pathways, growth 
and transcription factors and/or cell cycle regulatory 
molecules during pregnancy may allow breast epithelial 
cells to become less proliferative and more resistant to 
carcinogenesis [6, 14]. Of particular significance are 
mammary stem/progenitor cells which represent an ideal 
target for malignant transformation due to their self-
renewing capacity and longevity [15, 16]. 
Meier-Abt et al. [17] analyzed the cell fate hypothesis 
in various mammary epithelial cell subpopulations in 
mice. In this study, mammary glands of parous and 
virgin mice were harvested, and gene-expression profiles 
and differentiation/proliferation potentials of specific 
mammary subpopulations were analyzed. In addition, the 
mammary glands of parous and age matched virgin control 
mice were immunohistochemically analyzed for the 
expression of estrogen receptor α-, progesterone receptor 
(PR), Versican, and β-catenin. The Versican gene encodes 
for an extracellular proteoglycan and represents one of the 
classic target genes of the Wnt pathway [17]. 
The results of their study suggested that in mice, 
early pregnancy leads to a reduced response of the 
mammary gland to progesterone, caused primarily by a 
decrease in the proportion of PR positive luminal cells. 
Consecutively, a downregulation of Wnt4 expression 
in the luminal epithelial cells, and a reduction of the 
Wnt signaling pathway in basal stem/progenitor cells 
was identified [17]. Wnt ligands, such as Wnt4 in 
breast, activate a signaling cascade of which the Wnt/β-
catenin-dependent pathway is best characterized [18, 
19]. Activation of the Wnt signaling pathway causes 
accumulation of β-Catenin in the nucleus, resulting in an 
interaction with transcription factors and expression of 
the respective target genes [18-20], which has been shown 
to promote tumorigenesis in mice [21] and promotes 
invasiveness of human breast cancer cells by interacting 
with the Hippo pathway [22]. On the other hand, 
downregulation of Wnt- signaling causes a persistent 
decrease of proliferation potential of basal mammary stem/
progenitor cells and an increased differentiation phenotype 
of mammary epithelial cells [17]. These findings suggest 
that the Wnt signaling pathway plays a crucial role in 
breast cancer carcinogenesis, which might be mediated by 
increased proliferation of mammary stem/progenitor cells 
[6].
In a second study, the authors demonstrated that the 
reduction of PR expressing cells and downregulation of 
Wnt signaling pathway in parous mice are of life-long 
duration [23], and that pregnancies in older animals have 
a limited effect on these parameters [23].
In humans, only a few studies have analyzed the 
effect of pregnancy on breast cancer cells. A decrease 
of PR positive luminal cells as well as Wnt signaling 
can also be observed in parous compared to nulliparous 
women [24, 25]. However, to our knowledge, a systematic 
analysis of the Wnt signaling pathway as well as PR 
expression in women with pregnancy at an early age 
compared to women with pregnancy at an older age and 
nulliparous women has not been conducted so far. The 
aim of the present study was to analyze whether the same 
mechanisms as described in mice might also play a role 
in the protective effect of early pregnancies against breast 
cancer in humans, in order to identify potential targets for 
breast cancer prevention strategies.
RESULTS
Of the 125 patients identified, 35 (28%) were 
nulliparous, 52 (42%) had full-term pregnancy before 
the age of 30 and 38 (30%) after the age of 30 (Table 
1). Within the nulliparous group, 23 (66%) did not 
have subsequent breast cancer (Group 1) and 12 (33%) 
developed subsequent breast cancer (Group 2). Within the 
group of women that had full-term pregnancy before the 
age of 30, 16 (31%) developed subsequent breast cancer 
(Group 3) whereas 36 (69%) did not have subsequent 
breast cancer (Group 4). Within the group of women that 
had full-term pregnancy after the age of 30, 16 (42%) 
developed subsequent breast cancer (Group 5) and 22 
(58%) did not have subsequent breast cancer (Group 6).
To determine if the pattern of expression of PR, 
Versican, Wnt4, CK15 and β-Catenin in benign breast 
tissues differed between the groups, we performed 
an immunohistochemical analysis for these markers. 
Representative staining for Versican, Wnt4 and PR are 
shown in Figures 1 to 3. For nulliparous women, the 
number of PR positive epithelial cells was significantly 
higher in the subgroup with subsequent breast cancer 
compared to those without subsequent cancer (p = 
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0.029, Mann-Whitney U test) (Figure 4a). Additionally, 
we observed that the number of PR positive epithelial 
cells was significantly higher in the group of nulliparous 
women with subsequent invasive breast cancer (Group 2) 
compared to the group of women with early pregnancy 
and no subsequent breast cancer (Group 4, p = 0.0135, 
Mann-Whitney U test) (Figure 4b). There was also a 
trend toward higher numbers of PR positive cells in the 
nulliparous women with subsequent cancer (Group 2) 
when compared to the women with late pregnancy and 
no subsequent cancer, but it did not reach statistical 
significance (Group 6, p = 0.0705, Mann-Whitney U test, 
data not shown).
Within the group of women without subsequent 
breast cancer, we detected a significantly higher number 
of Wnt4-positive cells in the group of nulliparous women 
(Group 1) compared to the group of women with early 
pregnancy (Group 4, p = 0.0449) (Supplementary Figure 
1). Interestingly, there was also a significantly higher 
number of Wnt4-positive cells in the nulliparous group 
with subsequent breast cancer (Group 2) when compared to 
the early pregnancy group without breast cancer (Group 4, 
p  = 0.0229, Mann-Whitney U test, Supplementary Figure 
1). Overall, independent of subsequent breast cancer, the 
number of Wnt4-positive cells was significantly higher in 
nulliparous women (Groups 1 and 2) compared to women 
with early pregnancy (Groups 3 and 4, p = 0.0241, Mann-
Whitney U test, Figure 4c), and compared to women 
with late pregnancy (Groups 5 and 6, p = 0.0374, Mann-
Whitney U test, Figure 4d). Additionally, a significantly 
higher number of Wnt4-positive cells in nulliparous with 
subsequent cancer group (Group 2) when compared to the 
late pregnancy group without subsequent breast cancer 
was found (Group 6, p = 0.0368, Mann-Whitney U test) 
(Figure 4e). 
For the Wnt target Versican, there was a significantly 
lower expression in the group of women with early 
pregnancy (Groups 3 and 4) compared to the women 
with late pregnancy (Groups 5 and 6, p < 0.0001, Fisher’s 
exact test) (Figure 4f). Within the subgroups of women 
without subsequent breast cancer, Versican expression was 
also significantly lower in women with early pregnancy 
(Group 4) compared to women with late pregnancy 
(Group 6, p < 0.0001, Fisher’s exact test) and compared to 
nulliparous women (Group 1, p = 0.0028, Fisher’s exact 
test) (Supplementary Figure 1). 
No association between PR (on a continuous 
scale) and Versican (on a continuous scale) in any of the 
individual groups could be found (p >0.05).
Table 1: Number of subjects and median age in each group based on age at first pregnancy and the occurrence of 
subsequent breast cancer.
Groups Number of patients
Age at first pregnancy 
(median) Age at cancer diagnosis (median)
1 
(nulliparous, no subsequent cancer) 25 - -
2 
(nulliparous, subsequent cancer) 10 - 35-79 (51)
3 
(early pregnancy, subsequent cancer) 16 18-29 (23) 34-71 (52)
4 
(early pregnancy, no subsequent cancer) 36 18-27 (21) -
5 
(late pregnancy, subsequent cancer) 16 33-38 (36) 39-69 (56)
6 
(late pregnancy, no subsequent cancer) 22 32-39 (37) -
Figure 1: Three representative cases for Versican staining. a: No detectible Versican expression in breast epithelial cells (0) b: 
Faint, predominantly nuclear Versican expression (1+) c: strong, cytoplasmic Versican expression (3+). Magnification 100x.
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For CK15 and β-Catenin, no significant difference 
in expression was detected between the different 
subgroups.
We also analyzed 7 breast cancer cases (3 from 
Group 2/nulliparous women, 2 from Group 3/early 
pregnancy and 2 from Group 5/late pregnancy) with 
immunohistochemistry against PR, Versican, Wnt4, CD15 
and β-Catenin. The number of cases was too small for a 
statistical analysis, but looking at the results there were 
no differences between the cancer cases. 3 breast cancers 
were completely negative for PR, and all but one were 
negative for Wnt-4 and Versican. It thus seems as if in 
these few available breast cancer cases, there was no 
particular activation of the Wnt-pathway.
DISCUSSION
In the present study, we performed 
immunohistochemistry for PR, Wnt4, Versican, β-catenin 
and CK-15 on breast tissue from different subpopulations 
of women, stratified according to age at first pregnancy 
and occurrence of breast cancer. In accordance to 
correspondent mouse studies [17, 23], we found 
significantly more PR and Wnt4 positive epithelial cells 
in nulliparous women with subsequent invasive breast 
cancer compared to women with early pregnancy and 
no subsequent breast cancer. Furthermore, the number 
of Wnt4 positive cells in women with either early or late 
pregnancy was significantly lower when compared to that 
in nulliparous women, independent of subsequent breast 
cancer occurrence. By contrast, the expression of Versican 
Figure 3: Two representative cases for PR staining. a. few PR-positive cells in a lactiferous duct. b. lobule with almost all epithelial 
cells with PR expression. Magnification 200x.
Figure 2: Two representative cases for Wnt4 staining. a. No detectible Wnt4 expression in breast epithelial cells b. Wnt4 expression 
in a subset of epithelial cells. Magnification 200x.
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in breast epithelial cells was significantly lower in women 
with an early pregnancy compared to nulliparous women 
and to women with a late pregnancy, also independent of 
subsequent breast cancer occurrence. 
In accordance with the results of our study, PR 
positive cells are reduced not only in parous rodents, 
but also in parous humans [24, 26], when compared to 
nulliparous mice or humans. Despite the fact that in their 
study, Taylor et al. [24] analyzed breast tissue from women 
who had an induced abortion between the 5th and 23rd 
week of pregnancy, the reduction of PR positive epithelial 
cells was distinct when compared to nulliparous women. 
In their study, a possible association with subsequent 
breast cancer was not analyzed [24]. The results of our 
study indicate a significant impact of early pregnancy on 
the expression of PR in breast epithelial cells, supporting 
the results of the corresponding mouse study by Meier-Abt 
et al. [17, 23], who examined the cell-fate hypothesis on 
the level of gene expression in mice. Analogously, reduced 
Wnt signaling has also been found in parous women [25].
Meier-Abt et al. [17, 23] examined the cell-fate 
hypothesis on the level of gene expression in mice. They 
were able to identify a lifelong downregulation of the 
Wnt pathway after pregnancy, which may be caused via 
a downregulation of PR positive luminal cells in parous 
mice. Consequently, basal mammary stem/progenitor 
cells become less proliferative and epithelial cells show 
an increased differentiation phenotype [17], which may 
be the underlying mechanism for the protection of early 
pregnancy against breast cancer. Additionally, a decreased 
Wnt signaling has been found in parous women [25].
Our analysis of Wnt4 expression showed similarities 
to the results of PR. Additionally, expression of Wnt4 was 
significantly higher in nulliparous compared to parous 
women. However, since the number of cases evaluable 
for Wnt4 in our study was small (12 cases), further 
experiments to test this hypothesis are warranted.
By analyzing β-catenin, Versican and CK15, we 
examined important targets of the Wnt pathway. Although 
no significant difference was observed in the expression of 
Figure 4: Graphic depiction of PR, Wnt4 and Versican expression between different subgroups. Group 1&2: nulliparous 
women, Group 3&4: women with a full term pregnancy before the age of 30 years (early pregnancy), Group 5&6: women with a full term 
pregnancy after the age of 30 years (late pregnancy), Group 2: nulliparous women with subsequent breast cancer, Group 4: women with 
early pregnancy and no subsequent breast cancer. a. significantly lower numbers of PR+ epithelial cells in nulliparous women without 
subsequent breast cancer (Group 1) compared to nulliparous women with subsequent breast cancer (Group 2) b. significantly lower numbers 
of PR+ epithelial cells in women with early pregnancy and no subsequent breast cancer (Group 4) compared to nulliparous women with 
subsequent breast cancer (Group 2) c. significantly lower numbers of Wnt4+ epithelial cells in women with early pregnancy compared 
to nulliparous women. d. significantly lower numbers of Wnt4+ epithelial cells in women with late pregnancy compared to nulliparous 
women e. significantly higher number of Wnt4+ cells in nulliparous women with subsequent cancer (Group 2) when compared to the late 
pregnancy group without subsequent breast cancer (Group 6) f. significantly lower Versican expression in epithelial cells in women with 
early pregnancy (Group 1&2) compared to women with late pregnancy (Group 5&6).
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β-catenin and CK15, a Wnt target and an epithelial stem 
cell marker, respectively, between the various groups, 
we found a clear impact of pregnancy and, interestingly, 
early pregnancy, on the expression of Versican, with 
significantly lower expression in women with early 
pregnancy compared to those with late pregnancy and to 
nulliparous women. 
Our findings thus support the hypothesis that early 
pregnancy, possibly through a decrease of PR positive 
luminal cells, leads to a decreased activation of the Wnt- 
signaling pathway and subsequent lower expression of the 
Wnt target Versican, which, by inhibiting the proliferation 
of mammary stem/progenitor cells, may be the reason for 
the lower incidence of subsequent breast cancer in these 
women.
Nevertheless, the limiting factors of our study need 
to be addressed. First, the number of patients in each 
group is rather small and heterogeneous. Specifically, 
the number of cases that could be analyzed for Wnt4 was 
small. Despite the small sample size, we demonstrated 
a relationship between a higher expression of certain 
components of the Wnt pathway, such as PR, Wnt4 and 
Versican, and the occurrence of subsequent breast cancer.
CONCLUSIONS
This is the first study examining the effect of early 
pregnancy on PR expression and the activation of the 
canonical Wnt/ β-catenin pathway in human breast tissue. 
We demonstrated a lower expression of PR, Wnt4 and 
Versican in women with an early pregnancy compared to 
women with a late pregnancy and compared to nulliparous 
women. Our results suggest, in accordance with previous 
studies in mice, that the downregulation of epithelial 
Wnt signaling is associated with the protective effect of 
early pregnancy against breast cancer in humans. The 
reduction in Wnt signaling may occur through a decrease 
of PR-positive luminal cells, which results in a decreased 
expression of the PR target Wnt4 and the Wnt4 target 
Versican, and consequently in a decreased proliferation 
of stem/progenitor cells. The Wnt signaling cascade 
might thus represent a potential target for breast cancer 
prevention strategies and further studies to define the 
underlying molecular mechanisms are needed.
MATERIALS AND METHODS
Identification of patients
Based on the database of the Institute of Pathology 
at the University Hospital Basel and associated clinical 
information, a total of 125 women who underwent biopsy 
of benign breast tissue were identified. The cohort was 
divided into six groups based on age at first pregnancy 
and the occurrence of subsequent breast cancer (Table 
1). Early pregnancy was defined as a full-term pregnancy 
before the age of 30, and late pregnancy as a full-term 
pregnancy after the age of 30. Additionally, 7 breast cancer 
cases from the subgroups with subsequent cancers were 
identified. The corresponding tissue blocks for each patient 
were collected from the archives, and new hematoxylin 
& eosin (HE) slides were prepared. All HE slides were 
reviewed by an experienced breast pathologist (S.M.), and 
one appropriate slide containing benign breast tissue was 
identified for each patient. The study was performed in 
accordance with the Swiss patient privacy laws and has 
been approved by the Ethikkommission Nordwest- und 
Zentralschweiz (EKNZ, proposal number 2014-397).
Immunohistochemistry
From each appointed tissue block selected 
based on the HE slides, 4μm sections were cut. 
Immunohistochemical analyses were performed by 
using reagents specific for PR (Clone 790-2223, 
Ventana, prediluted), Versican (polyclonal, Booster, 
1:50), Cytokeratin(CK)15 (Clone 28476, Abcam, 
1:200), β-Catenin (Clone 760-4242, Ventana, prediluted) 
and Wnt4 (Clone 150596, Abcam, 1:50). For all 
immunohistochemical stainings, DAB was used as a 
chromogen. All antibodies were extensively tested and 
validated using normal breast tissue (progesterone), 
normal thyroid tissue (Wnt4), normal brain tissue 
(Versican), normal esophagus (CK15) and desmoid tumors 
(β-Catenin).
Immunohistochemical analyses were performed by 
R.M and S.M., blinded for the subgroups of the patients. 
For PR, Wnt4, CK15 and β-Catenin, 200 breast epithelial 
cells were counted and the number of positive cells for 
each marker was recorded. For Versican, the staining was 
scored as: 0 = absent staining, 1 = only nuclear staining, 2 
= weak cytoplasmic staining, and 3 = strong cytoplasmic 
staining of epithelial cells. For statistical analyses, 0 
andd were considered negative for Versican, and 2 and 3 
(cytoplasmic staining) were considered positive. Examples 
of staining for Versican and Wnt4 are given in Figures 1 
and 2. 
Statistical analysis
Statistical analyses for categorical and non-
categorical variables were performed using Fisher’s Exact 
and Mann-Whitney U tests. All tests were two-sided. 
P-values < 0.05 were considered statistically significant. 
All analyses were performed using Graphpad Prism 6.0 
(Graphpad Software, Inc., La Jolla, CA) or SPSS v.20 
(Endicott, New York, NY).
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